Optimization of lymphapheresis for manufacturing autologous CAR-T cells

Ikumi Yamanaka, Takuji Yamauchi, Tomoko Henzan, Teppei Sakoda, Kyoko Miyamoto, Hiroyuki Mishima, Hiroaki Ono, Yuhki Koga, Yasuhiro Nakashima, Koji Kato, Toshihiro Miyamoto, Shinichi Mizuno, Yoshihiro Ogawa, Shouichi Ohga, Koichi Akashi, Takahiro Maeda, Yuya Kunisaki

研究成果: Contribution to journalArticle査読

抄録

Collection of CD3+ lymphocytes via lymphapheresis is essential for manufacturing autologous chimeric antigen receptor (CAR) T cells. Optimization of timing and procedures for lymphapheresis for each patient is critical because patients often have progressive diseases and receive medications that could reduce T cell counts. We conducted a retrospective study of clinical data from 28 patients who underwent lymphapheresis for CD19-directed CAR-T therapy with tisagenlecleucel to identify factors that could affect CD3+ lymphocyte yields. The numbers of CD3+ cells in peripheral blood were significantly correlated with CD3+ cell yields (correlation coefficient r = 0.84), which enabled us to estimate the volume of blood to process before apheresis. We also found that small cell ratio (SCR) at the apheresis site precisely reflected the proportion of lymphocytes, especially in patients without circulating blasts (coefficient of determination: r2 = 0.9). We were able to predict the CD3+ cell yield and prevent excessive apheresis by measuring pre-apheresis circulating CD3+ cell counts and monitoring SCR. Collectively, these results will help us to establish a strategy for optimization of lymphapheresis procedures for CAR-T cell production on a patient-by-patient basis.

本文言語英語
ページ(範囲)449-458
ページ数10
ジャーナルInternational journal of hematology
114
4
DOI
出版ステータス出版済み - 10 2021

All Science Journal Classification (ASJC) codes

  • 血液学

フィンガープリント

「Optimization of lymphapheresis for manufacturing autologous CAR-T cells」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。

引用スタイル